CGP 55128A
Latest Information Update: 30 May 2001
Price :
$50 *
At a glance
- Originator Novartis
- Class Antihypertensives
- Mechanism of Action Renin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Hypertension
Most Recent Events
- 30 May 2001 Profile reviewed but no significant changes made
- 10 Jul 1998 No-Development-Reported for Hypertension in Switzerland (PO)
- 04 Dec 1995 New profile